| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.1.4.59 | Staphylococcus aureus | - |
- |
- |
| 3.1.4.59 | Staphylococcus aureus RN4220 | - |
- |
- |
| EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.1.4.59 | cyclic di-3',5'-adenylate + H2O | - |
Staphylococcus aureus | 5'-O-phosphonoadenylyl-(3'->5')-adenosine | - |
? | |
| 3.1.4.59 | cyclic di-3',5'-adenylate + H2O | - |
Staphylococcus aureus RN4220 | 5'-O-phosphonoadenylyl-(3'->5')-adenosine | - |
? |
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.1.4.59 | gdpP | - |
Staphylococcus aureus |
| EC Number | General Information | Comment | Organism |
|---|---|---|---|
| 3.1.4.59 | physiological function | mutations within the GdpP gene, allow both laboratory and clinical isolates of Staphylococcus aureus to grow without lipoteichoic acid. Intracellular c-di-AMP levels increase drastically in GdpP deletion strains and in an lipoteichoic acid-deficient suppressor strain. An increased amount of cross-linked peptidoglycan is observed in the GdpP mutant strain. GdpP mutant strains display a 13-22% reduction in the cell size due to increased c-di-AMP levels | Staphylococcus aureus |